{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:41:14Z","timestamp":1792636874629,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"DOI":"10.1186\/s13098-026-02250-9","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T12:24:51Z","timestamp":1785155091000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the therapeutic benefits and safety of ecnoglutide for type 2 diabetes: evidence from a systematic review and meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"given":"Saaed","family":"Abunada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abunada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Vivek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakhveer","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Muskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyanth","family":"Parkash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saqlain","family":"Nazeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Anchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fnu","family":"Danial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashish","family":"Turesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amjad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan","family":"Qureshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahir","family":"Tesfaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"issue":"10397","key":"2250_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736","volume":"402","author":"KL Ong","year":"2023","unstructured":"Ong KL, Stafford LK, McLaughlin SA, Boyko EJ, Vollset SE, Smith AE, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203\u201334. https:\/\/doi.org\/10.1016\/S0140-6736. (23)01301-6 PubMed PMID: 37356446.","journal-title":"Lancet"},{"key":"2250_CR2","doi-asserted-by":"publisher","unstructured":"Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022;183. https:\/\/doi.org\/10.1016\/j.diabres.2021.109119 . PubMed PMID: 34879977.","DOI":"10.1016\/j.diabres.2021.109119"},{"issue":"17","key":"2250_CR3","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.3390\/ijms21176275","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of Type 2 Diabetes Mellitus. Int J Mol Sci 2020. 2020;21(17):6275. https:\/\/doi.org\/10.3390\/ijms21176275 . PubMed PMID: 32872570.","journal-title":"Int J Mol Sci 2020"},{"issue":"2","key":"2250_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1586\/17512433.2016.1121808","volume":"9","author":"L \u00d8stergaard","year":"2016","unstructured":"\u00d8stergaard L, Frandsen CS, Madsbad S. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review. Expert Rev Clin Pharmacol. 2016;9(2):241\u201365. https:\/\/doi.org\/10.1586\/17512433.2016.1121808 . PubMed PMID: 26573176.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2250_CR5","doi-asserted-by":"crossref","unstructured":"Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021;12. 10. 1177\/2042018821997320 PubMed PMID: 33767808.","DOI":"10.1177\/2042018821997320"},{"issue":"5","key":"2250_CR6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, Sargin M, Karsb\u00f8l JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341\u201354. https:\/\/doi.org\/10.1016\/S2213-8587. (17)30092-X PubMed PMID: 28385659.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2250_CR7","doi-asserted-by":"publisher","unstructured":"Guo W, Xu Z, Zou H, Li F, Li Y, Feng J, et al. Discovery of ecnoglutide \u2013 A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog. Mol Metab. 2023;75. https:\/\/doi.org\/10.1016\/j.molmet.2023.101762 . PubMed PMID: 37364710.","DOI":"10.1016\/j.molmet.2023.101762"},{"key":"2250_CR8","doi-asserted-by":"crossref","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372. 10.1136. \/BMJ.N71 PubMed PMID: 33782057.","DOI":"10.1136\/bmj.n71"},{"key":"2250_CR9","doi-asserted-by":"crossref","unstructured":"Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358. 10. 1136\/BMJ.J4008 PubMed PMID: 28935701.","DOI":"10.1136\/bmj.j4008"},{"key":"2250_CR10","doi-asserted-by":"publisher","DOI":"10.70389\/PJS.100082","author":"R Agha","year":"2025","unstructured":"Agha R, Mathew G, Rashid R, Kerwan A, Al-Jabir A, Sohrabi C, et al. Transparency In The reporting of Artificial INtelligence \u2013 the TITAN guideline. Premier J Sci. 2025. https:\/\/doi.org\/10.70389\/PJS.100082.","journal-title":"Premier J Sci"},{"key":"2250_CR11","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000004512","author":"O Abunada","year":"2025","unstructured":"Abunada O, Hassan F, Kumar N, Kumar S, Majeed I, Batra K, et al. Efficacy and safety of SGLT2 inhibitor empagliflozin in T2DM with established cardiovascular disease: a systematic review and meta-analysis of RCTs. Ann Med Surg (Lond). 2025. https:\/\/doi.org\/10.1097\/MS9.0000000000004512.","journal-title":"Ann Med Surg (Lond)"},{"issue":"7414","key":"2250_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557 . PubMed PMID: 12958120.","journal-title":"BMJ"},{"issue":"1","key":"2250_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/S40200-025-01853-9","volume":"25","author":"A Basit","year":"2026","unstructured":"Basit A, Kumar S, Ahmed H, Babar R, Saeed SS, Siddiqui TA, et al. Impact of oral magnesium supplementation on glycemic and cardiometabolic outcomes in prediabetic adults: a systematic review and meta-analysis. J Diabetes Metabolic Disorders 2026. 2026;25(1):1. https:\/\/doi.org\/10.1007\/S40200-025-01853-9.","journal-title":"J Diabetes Metabolic Disorders 2026"},{"key":"2250_CR14","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. 10.1136. \/BMJ.L4898 PubMed PMID: 31462531.","DOI":"10.1136\/bmj.l4898"},{"key":"2250_CR15","unstructured":"GRADE | Cochrane [Internet]. [cited 2026 Jan 14]. Available from: https:\/\/www.cochrane.org\/learn\/courses-and-resources\/cochrane-methodology\/grade"},{"issue":"1","key":"2250_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-025-68165-7","volume":"17","author":"D Zhu","year":"2026","unstructured":"Zhu D, Wang W, Tong G, Ma J, Wen B, Zheng X, et al. Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Nat Commun 2026. 2026;17(1):1. https:\/\/doi.org\/10.1038\/s41467-025-68165-7 . PubMed PMID: 41501026.","journal-title":"Nat Commun 2026"},{"issue":"10","key":"2250_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-8587(","volume":"13","author":"Y He","year":"2025","unstructured":"He Y, Mi N, Cheng Z, Xue H, Han J, Wang H, et al. Efficacy and safety of cAMP-biased GLP-1 receptor agonist ecnoglutide versus dulaglutide in patients with type 2 diabetes and elevated glucose concentrations on metformin monotherapy (EECOH-2): a 52-week, multicentre, open-label, non-inferiority. randomi\u2026 Lancet Diabetes Endocrinol. 2025;13(10):863\u201373. https:\/\/doi.org\/10.1016\/S2213-8587(. 25)00196-2 PubMed PMID: 40854315.","journal-title":"randomi\u2026 Lancet Diabetes Endocrinol"},{"issue":"1","key":"2250_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024","volume":"15","author":"D Zhu","year":"2024","unstructured":"Zhu D, Wang W, Tong G, Ma G, Ma J, Han J, et al. Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Commun 2024. 2024;15(1):1. https:\/\/doi.org\/10.1038\/s41467-024-. 52353-y PubMed PMID: 39333121.","journal-title":"Nat Commun 2024"},{"key":"2250_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1431292","volume":"15","author":"QK Liu","year":"2024","unstructured":"Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292. https:\/\/doi.org\/10.3389\/fendo.2024.1431292.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2250_CR20","doi-asserted-by":"publisher","first-page":"e2231982","DOI":"10.1001\/jamanetworkopen.2022.31982","volume":"5","author":"W Ghusn","year":"2022","unstructured":"Ghusn W, De La Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, et al. Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA Netw Open. 2022;5(9):e2231982. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.31982 . PubMed PMID: 36121652.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"2250_CR21","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S2213","volume":"13","author":"L Ji","year":"2025","unstructured":"Ji L, Gao L, Xue H, Tian J, Wang K, Jiang H, et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(9):777\u201389. https:\/\/doi.org\/10.1016\/S2213. -8587(25)00141-X PubMed PMID: 40555243.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2250_CR22","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/bph.15497","volume":"179","author":"B Jones","year":"2022","unstructured":"Jones B. The therapeutic potential of GLP-1 receptor biased agonism. Br J Pharmacol. 2022;179(4):492\u2013510. https:\/\/doi.org\/10.1111\/bph.15497 . PubMed PMID: 33880754.","journal-title":"Br J Pharmacol"}],"container-title":["Diabetology & Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02250-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02250-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-026-02250-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:26:11Z","timestamp":1792635971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-026-02250-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2250"],"URL":"https:\/\/doi.org\/10.1186\/s13098-026-02250-9","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This manuscript was not commissioned.","order":4,"name":"Ethics","label":"Peer and provenance statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"222"}}